Effect of isocarbacyclin methyl ester incorporated into lipid microspheres on cutaneous blood flow in rat.
A new stable prostacyclin analogue, isocarbacyclin methyl ester (CAS 88931-51-5, TEI-9090), incorporated into lipid microspheres (TTC-909), was examined for its effects on cutaneous blood flow and mean blood pressure in rats in comparison with PGE1 (LM) (prostaglandin E1 in lipid microspheres). TTC-909 at 0.3 micrograms/kg i.v. significantly increased the sole cutaneous blood flow without changing blood pressure. A significant decrease in mean blood pressure was observed with TTC-909 above 1 microgram/kg i.v. PGE1 (LM) also showed a decrease in the blood pressure from 1 microgram/kg i.v., whereas the sole cutaneous blood flow was not affected even at 10 micrograms/kg i.v. These results suggest that TTC-909 dilates the skin vessels preferentially to other blood vessels in the rat and that effect is more potent than that of PGE1 (LM). TTC-909 may thus prove to be an effective agent for the treatment of peripheral vascular disease.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004337:Drug Carriers; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D066298:In Vitro Techniques; D008081:Liposomes; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply*; D014665:Vasodilator Agents / Q000494:pharmacology*
D004337:Drug Carriers; D008081:Liposomes; D010975:Platelet Aggregation Inhibitors; C068518:TTC 909; D014665:Vasodilator Agents; D011464:Epoprostenol